Exacerbation of IgA nephropathy in a patient receiving dupilumab

Exacerbation of IgA nephropathy in a patient receiving dupilumab

Bibliographic Details
Main Authors:	Masako Yamamoto, MD, Yuriko Kawase, MD, PhD, Emi Nakajima, MD, PhD, Yoshiaki Matsuura, MD, PhD, Wataru Akita, MD, PhD, Ryousuke Aoki, MD, PhD, Yusuke Suzuki, MD, PhD, Hiroshi Mitsui, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	JAAD Case Reports
Subjects:	atopic dermatitis dupilumab IgA nephropathy renal dysfunction toll-like receptor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512622000352

Similar Items

Vitiligo during dupilumab therapy
by: Vincenzo Picone, MD, et al.
Published: (2023-06-01)

Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series
by: Shuhei Hara, MD, et al.
Published: (2023-05-01)

Dupilumab in HIV-positive patients: A case series report of 4 patients
by: Ameen Alawadhi, MD, et al.
Published: (2020-12-01)

Persistent Neutrophil Infiltration and Unique Ocular Surface Microbiome Typify Dupilumab–Associated Conjunctivitis in Patients with Atopic Dermatitis
by: VijayKumar Patra, PhD, et al.
Published: (2024-01-01)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
by: Neda Shahriari, MD, et al.
Published: (2023-03-01)

Resolution of dupilumab-associated alopecia areata with dosage modification
by: Maansi Kulkarni, BS, et al.
Published: (2022-04-01)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
by: Danielle M. Peterson, MD, et al.
Published: (2021-04-01)

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesCapsule Summary
by: Angela L. Bosma, MD, et al.
Published: (2023-03-01)

Severe atopic dermatitis with cutis laxa caused by a variant in the ELN gene
by: Tatsuya Katsumi, MD, et al.
Published: (2024-04-01)

Pyoderma gangrenosum developing in a patient treated with dupilumab
by: Jessica Nasseh, MD, et al.
Published: (2022-02-01)

De novo case of lichenoid eruption following dupilumab treatment
by: Tae-Eun Kim, MD, et al.
Published: (2021-07-01)

Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient
by: Albert E. Zhou, MD, PhD, et al.
Published: (2022-11-01)

The ability of biomarkers to assess the severity of atopic dermatitis
by: Takeshi Nakahara, MD, PhD, et al.
Published: (2024-02-01)

Did dupilumab unmask smoldering mycosis fungoides?
by: Michelle Toker, BS, et al.
Published: (2023-08-01)

A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients
by: Edward I. Herman, MD, PhD, et al.
Published: (2024-04-01)

Treatment of lichen sclerosus and hypertrophic scars with dupilumab
by: Danielle M. Peterson, MD, et al.
Published: (2022-05-01)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
by: Marissa Ayasse, BS, et al.
Published: (2021-01-01)

Pembrolizumab-induced lichenoid dermatitis treated with dupilumab
by: Jonathan J. Park, PhD, et al.
Published: (2023-07-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Successful treatment of subcorneal pustular dermatosis targeting an underlying monoclonal IgA gammopathy
by: Ina Kreyberg, MD, PhD, et al.
Published: (2023-11-01)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
by: Jorge R. Georgakopoulos, MD, et al.
Published: (2021-09-01)

Successful treatment of refractory IgA vasculitis with tofacitinib
by: Yi-Fei Xu, MD, et al.
Published: (2022-12-01)

Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023-12-01)

Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab
by: Dmitry Nedosekin, PhD, et al.
Published: (2021-03-01)

Pemphigoid gestationis treated with dupilumab
by: Rita E. Chen, BA, et al.
Published: (2023-11-01)

Birth mode is associated with development of atopic dermatitis in infancy and early childhood
by: Sveinung T. Hoel, MD, et al.
Published: (2023-08-01)

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series
by: Shusaku Hosono, MD, et al.
Published: (2020-06-01)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023-01-01)

Identification of biologic-responsive phenotypes in elderly people with eosinophilic asthma
by: Olga Prokunina, MD, et al.
Published: (2024-02-01)

Dupilumab-induced erythema nodosum
by: Danielle E. Mustin, MEng, et al.
Published: (2022-01-01)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
by: Nicholas A. Trum, BS, et al.
Published: (2021-08-01)

A case of paradoxical fibrosis and development of morphea in a patient on dupilumab
by: Bina Kassamali, BA, et al.
Published: (2021-11-01)

Classification of atopic dermatitis phenotypes according to allergic sensitization by cluster analysis
by: Hye Yung Yum, M.D., Ph.D, et al.
Published: (2022-08-01)

Poromas with YAP1–MAML2 fusions in a poromatosis case
by: Masako Yamamoto, MD, et al.
Published: (2022-07-01)

The fetal/placental weight ratio is associated with the incidence of atopic dermatitis in female infants during the first 14 months: The Hamamatsu Birth Cohort for Mothers and Children (HBC Study)
by: Masako Matsumoto, MD, et al.
Published: (2020-06-01)

Alopecia areata after dupilumab for atopic dermatitis
by: Krystal Mitchell, MBA, et al.
Published: (2018-03-01)

Unanswered questions on the use of biologics in pediatric asthma
by: Antonio Nieto, MD, PhD, et al.
Published: (2023-11-01)

Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore
by: Yik Weng Yew, MBBS, MPH, PhD, et al.
Published: (2023-12-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
by: Tristan V.M. Bruijn, MD, et al.
Published: (2024-05-01)

Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: Real-life experience
by: Julián Londoño, MD, et al.
Published: (2023-04-01)